Drew Ranieri
Stock Analyst at Morgan Stanley
(1.26)
# 3,426
Out of 4,853 analysts
164
Total ratings
44.94%
Success rate
-12.33%
Average return
Main Sectors:
Stocks Rated by Drew Ranieri
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ORGO Organogenesis Holdings | Maintains: Equal-Weight | $4 → $6 | $2.97 | +102.02% | 4 | Mar 5, 2025 | |
| GMED Globus Medical | Upgrades: Overweight | $83 → $100 | $59.58 | +67.84% | 12 | Dec 2, 2024 | |
| SYK Stryker | Upgrades: Overweight | $370 → $445 | $384.38 | +15.77% | 9 | Dec 2, 2024 | |
| SIBN SI-BONE | Maintains: Overweight | $21 → $19 | $18.69 | +1.66% | 15 | Aug 6, 2024 | |
| IART Integra LifeSciences Holdings | Maintains: Underweight | $24 → $27 | $13.43 | +101.04% | 15 | Jul 15, 2024 | |
| TMCI Treace Medical Concepts | Maintains: Equal-Weight | $5.5 → $8 | $5.85 | +36.75% | 12 | Jul 15, 2024 | |
| STVN Stevanato Group | Maintains: Equal-Weight | $26 → $22 | $23.00 | -4.35% | 16 | Jul 15, 2024 | |
| NPCE NeuroPace | Maintains: Equal-Weight | $9.5 → $8 | $13.37 | -40.16% | 13 | Jul 15, 2024 | |
| ATEC Alphatec Holdings | Maintains: Overweight | $19 → $16 | $12.54 | +27.59% | 8 | Jul 15, 2024 | |
| OM Outset Medical | Maintains: Equal-Weight | $75 → $83 | $19.80 | +316.67% | 10 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $38 | $18.74 | +102.77% | 9 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $88 → $96 | $70.07 | +37.01% | 10 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $28 → $26 | $12.41 | +109.51% | 8 | May 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $290 → $295 | $172.46 | +71.05% | 2 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $236 → $280 | $123.67 | +126.41% | 5 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $5 | $6.51 | -23.20% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $70 | $30.25 | +131.40% | 4 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $325 → $300 | $563.55 | -46.77% | 6 | Apr 25, 2022 |
Organogenesis Holdings
Mar 5, 2025
Maintains: Equal-Weight
Price Target: $4 → $6
Current: $2.97
Upside: +102.02%
Globus Medical
Dec 2, 2024
Upgrades: Overweight
Price Target: $83 → $100
Current: $59.58
Upside: +67.84%
Stryker
Dec 2, 2024
Upgrades: Overweight
Price Target: $370 → $445
Current: $384.38
Upside: +15.77%
SI-BONE
Aug 6, 2024
Maintains: Overweight
Price Target: $21 → $19
Current: $18.69
Upside: +1.66%
Integra LifeSciences Holdings
Jul 15, 2024
Maintains: Underweight
Price Target: $24 → $27
Current: $13.43
Upside: +101.04%
Treace Medical Concepts
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $5.5 → $8
Current: $5.85
Upside: +36.75%
Stevanato Group
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $26 → $22
Current: $23.00
Upside: -4.35%
NeuroPace
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $9.5 → $8
Current: $13.37
Upside: -40.16%
Alphatec Holdings
Jul 15, 2024
Maintains: Overweight
Price Target: $19 → $16
Current: $12.54
Upside: +27.59%
Outset Medical
Dec 4, 2023
Maintains: Equal-Weight
Price Target: $75 → $83
Current: $19.80
Upside: +316.67%
Nov 2, 2023
Maintains: Overweight
Price Target: $42 → $38
Current: $18.74
Upside: +102.77%
May 12, 2023
Maintains: Equal-Weight
Price Target: $88 → $96
Current: $70.07
Upside: +37.01%
May 4, 2023
Maintains: Underweight
Price Target: $28 → $26
Current: $12.41
Upside: +109.51%
Feb 3, 2023
Maintains: Overweight
Price Target: $290 → $295
Current: $172.46
Upside: +71.05%
Jan 6, 2023
Maintains: Equal-Weight
Price Target: $236 → $280
Current: $123.67
Upside: +126.41%
Nov 10, 2022
Maintains: Overweight
Price Target: $11 → $5
Current: $6.51
Upside: -23.20%
Oct 11, 2022
Maintains: Overweight
Price Target: $72 → $70
Current: $30.25
Upside: +131.40%
Apr 25, 2022
Maintains: Equal-Weight
Price Target: $325 → $300
Current: $563.55
Upside: -46.77%